Materials and Methods for Altering an Immune Response to Exogenous and Endogenous Immunogens, Including Syngeneic and Non-Syngeneic Cells, Tissues or Organs

Abstract

Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 11 / 918,908, filed Dec. 19, 2007, which is a U.S. national phase application of International Patent Application No. PCT / US2006 / 015555, filed Apr. 21, 2006, which claims priority to and the benefit of U.S. Provisional Patent Application No. 60 / 673,417, filed Apr. 21, 2005, and U.S. Provisional Patent Application No. 60 / 682,217, filed May 18, 2005, the contents of each being incorporated by reference herein.FIELD OF THE INVENTION[0002]This invention is directed to materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell-, tissue-, or organ-associated immunogen. For example, the present invention can modulate an adverse immune response or inflammatory reaction to exogenous or endogenous immunogens, including non-syngeneic or syngeneic cells, tissues or organs, as well as ameliorate an autoimmune con...

AI Technical Summary

Benefits of technology

"The present invention is about using a biocompatible matrix with anchored or embedded endothelial cells, endothelial-like cells, or analogs thereof to reduce an immune response or inflammation in a recipient. This can be done by providing an implantable material containing the matrix and cells prior to transplantation or administration of a cell, tissue, or organ transplant. The cells can also be used to induce immunological acceptance in a patient. The invention can be used in the treatment of autoimmune diseases and can reduce the immunogenicity of donor antigens. The cells can be autogenic, allogenic, xenogeneic, or genetically-modified variants of any cell type. The invention can also be used to reduce the immune response to non-syngeneic cells, tissues, or organs. Overall, the invention provides a method for using endothelial cells to modulate the immune response and promote graft acceptance."

Problems solved by technology

However, host immune responses present a formidable barrier to transplantation across species.

While such agents permit some degree of transplant acceptance, success is limited and perhaps of more significance, a patient's immune system is thoroughly compromised as a result of such agents.

Similarly, exogenous immunogens or stimuli have posed a clinical challenge.

These, too, can result in adverse immunological events or inflammatory reactions which necessitate treatment.

Successful management of such diseases has eluded clinicians to date.

Images